Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2010

01-05-2010 | Breast Oncology

p53 as a Marker of Prognosis in African-American Women with Breast Cancer

Published in: Annals of Surgical Oncology | Issue 5/2010

Login to get access

Abstract

Background

p53 overexpression has been identified as a poor prognostic marker in breast cancer. We investigate the value of p53 status within the context of stage and intrinsic subtype classification (subtype), in a group of African-American (AA) women of lower socioeconomic status (SES) with primary breast cancer.

Methods

Participants were 331 consecutive AA women treated at an urban hospital (median follow-up 41 months) with known subtype [luminal A = estrogen receptor (ER)+ and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 (HER2)−; luminal B = ER+ and/or PR+, HER2+; HER2+ = ER−, PR−, HER2+; basal = ER−, PR−, HER2−, cytokeratin (CK)5/6+, and/or HER1+; and unclassified = negative for all five markers] and p53 (Pab1801 antibody) immunohistochemical status. Proportional hazards regression models were used to select and evaluate factors prognostic for all-cause mortality.

Results

p53+ status was associated with grade 3 tumors, ER/PR– status, and basal subtype. On univariate analysis, factors related to survival were stage, grade [(3/1) hazard ratio (HR) = 2.64; 95% confidence interval (CI), 1.15–6.07], subtype [(ex. basal/luminal A) HR = 2.15; 95% CI, 1.34–3.45], and p53 status [(+/−) HR = 1.77; 95% CI, 1.15–2.72]. Multivariable modeling indicated that p53+ status remained a negative prognostic factor (HR = 1.63; 95% CI, 1.01–2.59) after adjustment for effects of age, stage, grade, and subtype; 5-year adjusted survival was significantly greater for p53− (66.7%) than p53+ cases (54.7%).

Conclusion

p53 status is an independent predictor of survival after consideration of other strong prognostic factors such as stage, tumor grade, and subtype, and thus may be useful in identifying AA women at high risk of breast cancer mortality.
Literature
1.
2.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRefPubMed
3.
Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272(12):947–54.CrossRefPubMed
4.
Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005;35:88–95.
5.
Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26(1):1–10.CrossRefPubMed
6.
Dookeran K, Gao X, Wang Y, et al. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. AACR Meeting Abstracts. April 14, 2007 2007;2007(1_Annual_Meeting):2510.
7.
Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368.CrossRefPubMed
8.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–8.CrossRefPubMed
9.
DeNavas-Walt C, Proctor BD, Lee CH. Income, Poverty, and Health Insurance Coverage in the United States: 2005. U.S. Census Bureau, Current Population Reports, U.S. Government Printing Office, Washington, DC. 2006:60–231.
10.
Dookeran KA, Ferrer K, Sekosan M, et al. p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women. J Clin Oncol (Meeting Abstracts). 2006;24(18_suppl):10001.
11.
Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994;343(8907):1195–7.CrossRefPubMed
12.
Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55(7):1485–90.PubMed
13.
Shiao YH, Chen VW, Wu XC, et al. Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo. 1996;10(2):169–173.PubMed
14.
Oliveira AM, Fletcher JA, Ross JS. Tumor Suppressor Genes in Breast Cancer: The Gatekeepers and the Caretakers. Pathol Patterns Rev. 2005;124(1):16–28.CrossRef
15.
Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86(9):705–12.CrossRefPubMed
16.
Jones BA, Kasl SV, Howe CL, et al. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004;101(6):1293–301.CrossRefPubMed
17.
Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer. 2004;100(12):2533–42.CrossRefPubMed
18.
19.
20.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.CrossRefPubMed
21.
Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. IARC; 2003.
22.
Fleming ID, Cooper JS, Hensen DE (editors). AJCC cancer staging manual, 5 ed. Philadelphia: Lippincott-Raven; 1998.
23.
Greene FL Page DL, Fleming ID (editors). AJCC cancer staging manual, 6 ed. New York: Springer Verlag; 2002.
24.
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.CrossRefPubMed
25.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155–68.PubMed
26.
Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer Verlag; 2003.
27.
Makuch RW. Adjusted survival curve estimation using covariates. J Chronic Dis. 1982;35(6):437–44.CrossRefPubMed
28.
Troester MA, Herschkowitz JI, Oh DS, et al. Gene expression patterns associated with p 53 status in breast cancer. BMC Cancer. 2006;6(1):276.CrossRefPubMed
29.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869.CrossRefPubMed
30.
Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.CrossRefPubMed
31.
Levine AJ, Hu W, Feng Z. Tumor suppressor genes. In: Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB, editors. The molecular basis of cancer, 3rd ed. Philadelphia: Saunders Elsevier; 2008:31–8.
32.
Dookeran KA, Gao X, Wang Y, Lukaszczyk B, DeLaTorre R, Roman G, Ferrer K, Sekosan M, McCaskill-Stevens W, Zaren HA. p53 gene mutations in African-American women with breast cancer. Breast Cancer Res Treat. 2006;100(Supplement 1):(December 2006):S145.
33.
Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. JNCI. 1992;84(11):845–55.PubMed
34.
Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. JNCI. 1993;85(3):200–6.PubMed
35.
Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L, Coplete J. Sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029–34.CrossRefPubMed
36.
Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8:R66.CrossRefPubMed
37.
Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6(1):50–6.PubMed
38.
39.
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMed
Metadata
Title
p53 as a Marker of Prognosis in African-American Women with Breast Cancer
Publication date
01-05-2010
Published in
Annals of Surgical Oncology / Issue 5/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0889-3

Other articles of this Issue 5/2010

Annals of Surgical Oncology 5/2010 Go to the issue

Translational Research and Biomarkers

p21 Waf1/Cip1 Polymorphisms and Risk of Esophageal Cancer

Translational Research and Biomarkers

Difference Between Proximal and Distal Microsatellite-Unstable Sporadic Colorectal Cancers: Analysis of Clinicopathological and Molecular Features and Prognoses

Gastrointestinal Oncology

Suitability of 7th UICC N Stage for Predicting the Overall Survival of Gastric Cancer Patients After Curative Resection in China

Colorectal Cancer

High Level of Notch1 Protein is Associated with Poor Overall Survival in Colorectal Cancer

Hepatobiliary and Pancreatic Tumors

Resection Margin and Recurrence-Free Survival After Liver Resection of Colorectal Metastases

Colorectal Cancer

Anterior Perineal PlanE for Ultralow Anterior Resection of the Rectum (The APPEAR Technique): A Video Demonstration